Nicotinic Acid Intestinal Release Lipid Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia and related metabolic disorders, such as non-alcoholic fatty liver disease (NAFLD) and atherosclerosis, face limitations in efficacy, side effects, and systemic exposure, with a need for pharmaceuticals that can beneficially influence intestinal microbiota to improve lipid metabolism independently of statin therapy.
Innovation Solution
A pharmaceutical composition containing nicotinic acid and/or nicotinamide, designed for controlled or delayed release to target the lower small intestine and colon, modifying the intestinal microbiota to improve blood lipid levels with minimal systemic exposure and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to treat dyslipidemia, then cardiovascular morbidity and mortality are reduced, but therapeutic utility is limited and cannot address remaining cardiovascular excess risk
Solution Approach 1:
The invention segments the therapeutic approach by dividing lipid metabolism regulation into two independent pathways: (1) hepatic cholesterol synthesis inhibition via statins, and (2) intestinal microbiota-mediated lipid metabolism modulation via nicotinic acid/nicotinamide. This segmentation allows statins to address one aspect of dyslipidemia while the microbiota-targeting compounds address remaining cardiovascular risk, providing complementary rather than competing mechanisms.
Solution Approach 2:
The invention merges two distinct therapeutic strategies into a comprehensive lipid management approach: conventional statin therapy targeting HMG-CoA reductase in the liver, combined with microbiota-modulating therapy using nicotinic acid or nicotinamide delivered to the intestine. This combination therapy addresses both established and remaining cardiovascular risk factors through synergistic mechanisms.
2Reliability
If nicotinic acid is administered systemically to improve lipid metabolism, then blood lipid levels are influenced, but side effects and systemic exposure increase
Solution Approach 1:
The invention applies local quality by delivering nicotinic acid or nicotinamide specifically to the intestinal lumen where microbiota reside, rather than systemic administration. The compounds exert their primary effect locally on gut bacteria composition and function, which in turn indirectly influences systemic lipid metabolism. This localized delivery minimizes direct systemic exposure and associated side effects while maintaining therapeutic efficacy through microbiota-mediated mechanisms.
Solution Approach 2:
The invention introduces intestinal microbiota as an intermediary between the administered compounds (nicotinic acid/nicotinamide) and the ultimate therapeutic target (systemic lipid metabolism). The compounds first modify microbiota composition and activity in the intestine, and these microbial changes then mediate the indirect regulation of blood lipid levels. This intermediary mechanism allows therapeutic effect with reduced direct systemic exposure compared to conventional nicotinic acid therapy.
3Adaptability or versatility
If pharmaceuticals are designed to target intestinal microbiota, then lipid metabolism can be improved independently of statin therapy, but delivery precision to lower small intestine and colon is required
Solution Approach 1:
The invention applies preliminary action by designing formulations that release nicotinic acid or nicotinamide at specific locations (lower small intestine and colon) before the compounds can be absorbed systemically. Enteric coatings and controlled-release mechanisms ensure the compounds reach their microbial target sites intact, allowing them to exert their microbiota-modulating effect locally before any systemic absorption occurs. This preliminary localized action prevents premature systemic exposure while ensuring targeted delivery to microbiota-rich regions.
Data Source
AI summary
The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.